Building or Buying Healthcare AI Is No Longer Just a Technology Decision

Healthcare organisations are under growing pressure to make smarter use of artificial intelligence. From clinical documentation and diagnostic support to patient flow, scheduling, cybersecurity, and even smart hospital equipment, AI capabilities are increasingly appearing across the healthcare environment.

This has made the familiar "build versus buy" question more complicated than ever.

Traditionally, health systems deciding between developing a solution internally or purchasing one from a vendor would focus on cost, implementation time, available technical talent, and the specific problem they were trying to solve. Those considerations still matter. However, AI introduces another major concern that cannot be treated as an afterthought: compliance.

The challenge is no longer simply deciding whether an AI tool is useful. Healthcare leaders must also understand where AI exists in their technology portfolio, what data it can access, how it makes decisions, who is responsible for monitoring it, and what happens when vendors update their products over time.

In a hospital environment, those are not minor details. They can affect privacy, cybersecurity, clinical safety, legal exposure, and patient trust.

AI Is Appearing Everywhere, Often Without a Clear Inventory

One of the most difficult parts of AI governance is that artificial intelligence is no longer limited to large, obvious projects.

Hospitals may intentionally deploy AI-powered clinical tools, but AI capabilities can also arrive quietly through software upgrades, cloud platforms, medical devices, imaging systems, patient engagement tools, and operational applications. Even equipment that once seemed purely physical, such as beds, monitoring systems, or workflow platforms, may now include intelligent automation, analytics, or predictive features.

That means many healthcare organisations may have more AI in use than they realise.

The issue is not necessarily that every AI-enabled upgrade is dangerous. The problem is visibility. If a hospital does not have a complete picture of where AI exists, it becomes difficult to assess risk, monitor performance, or ensure the technology is behaving within approved boundaries.

Healthcare organisations are generally used to tracking systems, devices, licences, and infrastructure assets. AI requires a broader level of oversight. Leaders need to know not only what software is installed, but also what data flows through it, what model features are activated, who can access it, and whether new capabilities have been introduced through vendor updates.

Without that visibility, the organisation may unknowingly allow sensitive information to be used in ways it never intended.

Compliance Must Be Built Into the AI Decision From Day One

For healthcare, AI compliance is not just about signing a contract or completing a procurement checklist.

It is about understanding the full lifecycle of the technology.

Before adopting an AI solution, hospitals need to ask important questions. What patient or organisational data will the system access? Will data leave the hospital environment? Does the vendor use customer data to improve its models? Who owns the outputs? How are permissions controlled? What happens when the solution is updated? Can the organisation audit usage, incidents, and decision-making behaviour?

These questions become especially important when vendors introduce AI features into products that are already in use.

A routine upgrade may sound harmless. However, a new AI function could change how data is processed, stored, shared, or analysed. It may also create new risks around access control, vendor visibility, and third-party integrations.

Healthcare organisations need a process that treats AI-enabled upgrades as meaningful changes, not just another software patch.

This does not mean every new feature should be rejected. It means every new capability should be reviewed with the same seriousness applied to other high-impact clinical, cybersecurity, privacy, and patient safety decisions.

Shadow AI Can Create Risks Outside Formal Governance

One of the growing concerns in healthcare is shadow AI.

Shadow AI happens when staff members, teams, or departments start using AI tools without going through the organisation's formal approval process. Sometimes this happens because people are trying to solve a real operational problem quickly. A clinician may experiment with an AI documentation assistant. An analyst may use an external chatbot to summarise information. A department may adopt an AI-enabled platform without fully understanding its data access requirements.

The intention may be positive, but the outcome can still create risk.

A solution developed by one person may later be shared with another. A tool initially used for a limited purpose may gradually become part of a wider workflow. Permissions may expand. Sensitive information may be entered into systems that were never formally assessed. Before long, an unofficial AI tool can become deeply embedded in daily operations.

That is why access management and governance are so important.

Healthcare organisations need clear policies around who can introduce AI tools, what data can be used, and what approvals are required before deployment. Staff should also have an easy way to bring forward useful ideas without feeling that the only option is to work around governance processes.

Strong governance should not stop innovation. It should make innovation safer and more sustainable.

The AI Lifecycle Needs More Attention Than the Initial Purchase

Many technology decisions focus heavily on the beginning of the journey. Teams assess vendors, compare features, negotiate contracts, and plan implementation. Once the system goes live, attention often moves to the next project.

AI cannot be managed that way.

An AI solution may change over time through software updates, new training data, revised algorithms, evolving regulations, security vulnerabilities, and changes in how users interact with it. A tool that appears safe and useful today may perform differently a year later.

That makes lifecycle management essential.

Healthcare organisations will need ongoing processes to monitor AI performance, detect unusual behaviour, review data access, reassess vendor commitments, and identify security issues before they become major problems. In some cases, AI itself may eventually help support this work by identifying vulnerabilities, monitoring system activity, and flagging patterns that humans might miss.

However, technology alone will not solve the governance challenge. There still needs to be clear accountability, regular review, and a defined process for deciding when a tool should be updated, paused, restricted, or retired.

The question should not only be, "Should we deploy this AI solution?"

It should also be, "Can we manage this solution responsibly for the next several years?"

When Buying Makes More Sense Than Building

For many health systems, purchasing an AI solution from an established vendor is often the most practical option.

Healthcare organisations are not software companies. They have finite technical resources, competing priorities, strict compliance requirements, and a responsibility to keep clinical operations running safely. Building an AI product internally can require significant investment in data engineering, model development, security controls, user experience design, integration work, testing, maintenance, and long-term support.

Even after a solution is built, the work is far from over.

Internal teams must continue to improve the product, manage changing requirements, address security issues, support users, and ensure the solution remains compliant as the environment evolves. That can become a major burden, particularly for hospitals already managing complex digital transformation programmes.

Buying can reduce some of that pressure, especially when the vendor has a proven track record, strong healthcare experience, and clear governance practices.

However, purchasing is not automatically the safer choice.

A vendor solution can still fail to meet expectations, create integration challenges, introduce unexpected costs, or become difficult to exit once the organisation is deeply committed. A poor fit can lead to a long and expensive relationship that does not deliver the promised value.

That is why healthcare leaders need to evaluate more than product features. They need to assess the vendor's ability to support the organisation over time.

When Building Internally May Be the Better Path

There are situations where building internally makes sense.

A health system may have a unique workflow, a highly specific patient population, or an operational challenge that existing vendors have not solved well. In these cases, a custom solution may offer greater flexibility and closer alignment with real clinical or business needs.

Internal development can also help organisations retain more control over their data, governance model, and future roadmap.

However, the decision should be made carefully.

Building an AI solution is not just about proving that something can be created. It is about whether the organisation can support it reliably, securely, and sustainably. A small successful prototype may be relatively easy to develop, but turning it into an enterprise-ready solution is much harder.

It must be integrated into existing systems, validated with real users, monitored for risk, supported by the IT team, and updated as regulations, technology, and workflows change.

The question is not simply whether a hospital can build a solution.

The more important question is whether it can maintain that solution without creating a new source of operational risk.

Start With the Problem, Not the Product

One of the strongest lessons for healthcare organisations is that AI should never be adopted just because it is available.

The starting point should always be the problem.

What workflow is creating delays, frustration, risk, or unnecessary cost? What outcome is the organisation trying to improve? What data is required? Who will use the solution? How will success be measured?

If a vendor does not understand the actual problem the health system is trying to solve, the partnership may already be heading in the wrong direction.

This is also important when considering whether the AI model is suitable for the hospital's patient population. An AI solution may perform well in one setting but not another. If the data used to train or validate the system does not reflect the communities being served, the technology may create biased, inaccurate, or less useful outcomes.

Healthcare AI cannot be treated as a generic product that works the same way everywhere.

The best outcomes come from collaboration between the health system and the vendor. Both sides need to learn from each other. Vendors need to understand the clinical environment, operational realities, patient populations, and workflow pressures. Healthcare organisations need to understand the technology's limitations, data requirements, and support model.

That shared learning process is essential.

AI Will Not Repair Broken Workflows

There is often a temptation to view AI as a shortcut.

When a process is slow, fragmented, or frustrating, AI can appear to be the answer. However, AI does not automatically fix poor workflows. In some cases, it can make existing weaknesses more visible or even amplify them.

A poorly designed workflow supported by AI may simply become a faster version of the same problem.

Before introducing AI, organisations should review the process itself. Is the workflow clear? Are responsibilities defined? Is the available data accurate? Are users already struggling with basic system usability? Are there gaps in training or communication?

If the underlying process is broken, AI may not deliver the expected benefit.

Technology works best when it supports a well-understood workflow, not when it is expected to rescue an unclear one.

The Value of Trusted Networks and Shared Learning

Healthcare organisations do not need to make every AI decision alone.

Trusted networks of peers, technology leaders, clinical experts, legal advisors, cybersecurity professionals, and experienced vendors can play an important role in helping organisations make better decisions. Learning from another hospital's implementation experience can reveal issues that are not obvious during a product demonstration.

Questions such as these can be extremely valuable:

No single factor will determine whether an AI project succeeds or fails. Cost matters. Governance matters. Clinical relevance matters. Integration matters. Vendor maturity matters. User acceptance matters.

The strongest decisions are usually made when organisations consider all of these factors together rather than focusing only on the latest AI feature.

Final Thoughts

Healthcare leaders are not simply choosing between building an AI solution or buying one from a vendor. They are making a long-term decision about governance, data protection, patient safety, cybersecurity, operational responsibility, and organisational capability.

The most effective AI strategy is not necessarily the fastest, cheapest, or most impressive on paper. It is the one that solves a real problem, fits the organisation's workflows, protects sensitive data, and can be managed responsibly over time.

AI has the potential to become a powerful force in healthcare. It can help teams work more efficiently, identify patterns earlier, reduce administrative burden, and support better decision-making.

However, it can also magnify existing gaps if organisations adopt it without clear oversight.

The real challenge is not simply choosing whether to build or buy. It is making sure that whichever path is chosen, the organisation is prepared to govern the technology from the first conversation through every update, integration, and decision that follows.